Status:
TERMINATED
ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
Lead Sponsor:
InSightec
Conditions:
Pain Resulting From Bone Metastases
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this enhanced surveillance study ("ESS") is to collect information regarding chronic adverse events that are possibly related to the ExAblate® System ("ExAblate") that are received by I...
Detailed Description
This proposed Registry will be performed in full compliance with all HIPAA rules and their implementations at potential participating sites. All patients planned to undergo the ExAblate procedure in a...
Eligibility Criteria
Inclusion
- This study collects safety data on patient treatments performed commercially under the FDA approved labeling.
- Eligibility is as per approved device indication.
- All registry-consented patients who undergo commercial ExAblate procedure for bone mets palliation after device approval.
Exclusion
Key Trial Info
Start Date :
June 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2017
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT01834937
Start Date
June 1 2013
End Date
April 1 2017
Last Update
November 9 2018
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
City of Hope
Duarte, California, United States, 91010
2
University of California San Francisco
San Francisco, California, United States, 94107
3
Stanford University
Stanford, California, United States, 94305
4
Mayo Clinic
Rochester, Minnesota, United States, 55905